本文選題：年齡相關(guān)性黃斑變性 + 貝伐單抗�。� 參考：《中國中醫(yī)眼科雜志》2016年02期

【摘要】：目的評(píng)價(jià)貝伐單抗(Bevacizumab)與雷珠單抗(Ranibizumab)玻璃體腔內(nèi)注射治療年齡相關(guān)性黃斑變性的全身安全性。方法計(jì)算機(jī)檢索Pubmed、EMbase、Cochrane Library、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(CBM)、中國知網(wǎng)(CNKI)、維普數(shù)據(jù)庫(VIP)、萬方數(shù)據(jù)庫,查找有關(guān)Bevacizumab與Ranibizumab治療年齡相關(guān)性黃斑變性的隨機(jī)對(duì)照研究(RCT),同時(shí)追索納入文獻(xiàn)的參考文獻(xiàn)。檢索時(shí)限均為從建庫至2013年12月1日。對(duì)納入研究的質(zhì)量進(jìn)行嚴(yán)格評(píng)價(jià)和資料提取,對(duì)符合質(zhì)量標(biāo)準(zhǔn)的RCT進(jìn)行Meta分析。結(jié)果共納入5個(gè)RCT,合計(jì)2382眼。各項(xiàng)研究中的全身安全性指標(biāo)同質(zhì)性較好,采用固定效應(yīng)模型進(jìn)行Meta分析。結(jié)果顯示:Bevacizumab組與Ranibizumab組相比,在總死亡率率[RR=1.093,95%CI(0.759,1.573)]、動(dòng)脈血栓事件發(fā)生率[RR=1.011,95%CI(0.673,1.520)]、中風(fēng)發(fā)生率[RR=0.830,95%CI(0.390,1.766)],非致死性心肌梗死發(fā)生率[RR=0.969,95%CI(0.482,1.951)],血管源性死亡發(fā)生率[RR=1.236,95%CI(0.627,2.436)],靜脈血栓事件發(fā)生率[RR=2.458,95%CI(0.986,6.131)]上均無統(tǒng)計(jì)學(xué)差異。結(jié)論 Meta分析結(jié)果表明Bevacizumab與Ranizumab治療年齡相關(guān)性黃斑變性具有相似的全身安全性,但尚需更多高質(zhì)量的前瞻性研究結(jié)果進(jìn)一步驗(yàn)證和支持。
[Abstract]:Objective to evaluate the safety of intravitreal injection of bevacizumab and Ranibizumab in the treatment of age-related macular degeneration. Methods computer search was conducted for Pubmedus EMbase Cochrane Library, Chinese Biomedical Literature Database (CBMN), CNKI, Weip Database and Wanfang Database. A randomized controlled study of Bevacizumab and Ranibizumab in the treatment of age-related macular degeneration was conducted and the references were also found. The time limit for retrieval is from the construction of the database to December 1, 2013. The quality of RCT was evaluated strictly and the data was extracted, and the RCT in accordance with the quality standard was analyzed by meta-analysis. Results A total of 5 RCTs were included, with a total of 2382 eyes. The homogeneity of systemic safety indexes in all studies was good, and fixed effect model was used for meta-analysis. 緇撴灉鏄劇ず:Bevacizumab緇勪笌Ranibizumab緇勭浉姣，

本文編號(hào)：2020990